Cargando…

Awakening p53 in senescent cells using nutlin-3

Detalles Bibliográficos
Autor principal:	Schug, Thaddeus T.
Formato:	Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2009
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815727/ https://www.ncbi.nlm.nih.gov/pubmed/20157556

Ejemplares similares

mTOR favors senescence over quiescence in p53-arrested cells
por: Schug, Thaddeus T.
Publicado: (2010)

Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
por: Huang, Baoying, et al.
Publicado: (2009)

Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme
por: Villalonga-Planells, Ruth, et al.
Publicado: (2011)

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
por: Aziz, Moammir H., et al.
Publicado: (2011)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Nutlin‐3a selects for cells harbouring TP 53 mutations
por: Kucab, Jill E., et al.
Publicado: (2016)

Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis
por: Lee, Dong Min, et al.
Publicado: (2017)

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
por: Yee-Lin, Voon, et al.
Publicado: (2018)

Awakening the kundalini of humour
por: Shetty, Harish
Publicado: (2006)

Nutlin-3 downregulates p53 phosphorylation on serine(392) and induces apoptosis in hepatocellular carcinoma cells
por: Shi, Xinli, et al.
Publicado: (2014)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
por: Sriraman, Anusha, et al.
Publicado: (2016)

The iPSC Awakens ANGPTL3 in Tangier Disease
por: Lee, Man K.S., et al.
Publicado: (2017)

Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
por: Tokalov, Sergey V, et al.
Publicado: (2010)

Nutlin-3a Nanodisks Induce p53 Stabilization and Apoptosis in a Subset of Cultured Glioblastoma Cells
por: Krishnamoorthy, A, et al.
Publicado: (2017)

Another "Janus paradox" of p53: induction of cell senescence versus quiescence
por: Darzynkiewicz, Zbigniew
Publicado: (2010)

Targeting Transcription Through Inhibition of TBP
por: Schug, Thaddeus T.
Publicado: (2011)

Sleepless nights in the ICU: the awaken family
por: Schmidt, Matthieu, et al.
Publicado: (2013)

Epigenetic therapies for neuroblastoma: immunogenicity awakens
por: Jiménez, Carlos, et al.
Publicado: (2023)

The p53 inducing drug dosage may determine quiescence or senescence
por: Lane, David P., et al.
Publicado: (2010)

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
por: Valentine, Jane M, et al.
Publicado: (2011)

Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma
por: Zheng, Tongsen, et al.
Publicado: (2014)

The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
por: Puszynski, Krzysztof, et al.
Publicado: (2014)

Awakening KDM5B to defeat leukemia
por: Chan, Lok Hei, et al.
Publicado: (2022)

Surprising sirtuin crosstalk in the heart
por: Schug, Thaddeus T., et al.
Publicado: (2010)

Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors
por: Chen, Hongsai, et al.
Publicado: (2018)

Synergistic Effect of Erastin Combined with Nutlin-3 on Vestibular Schwannoma Cells as p53 Modulates Erastin-Induced Ferroptosis Response
por: He, Weiwei, et al.
Publicado: (2022)

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
por: Haaland, Ingvild, et al.
Publicado: (2014)

Correction: The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
Publicado: (2015)

2020—The Year the World Was Awakened to the Importance of Supply Chain Management
por: Francis, James R., et al.
Publicado: (2021)

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation
por: Borthakur, Gautam, et al.
Publicado: (2015)

Synergistic activation of p53 by actinomycin D and nutlin-3a is associated with the upregulation of crucial regulators and effectors of innate immunity
por: Krześniak, Małgorzata, et al.
Publicado: (2020)

MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
por: Azer, Samy A.
Publicado: (2018)

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
por: Crane, Erin K., et al.
Publicado: (2015)

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
por: Meijer, A, et al.
Publicado: (2013)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
por: Kaindl, U, et al.
Publicado: (2014)

Transcriptome Analysis of Cells Exposed to Actinomycin D and Nutlin-3a Reveals New Candidate p53-Target Genes and Indicates That CHIR-98014 Is an Important Inhibitor of p53 Activity
por: Łasut-Szyszka, Barbara, et al.
Publicado: (2021)

Nutlin-3a for age-related macular degeneration
por: Chung, Hyewon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1fn7ebckag7b6vfkr5ltol0n5p